anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Systems and methods for automatically delivering medication to a user. A sensor coupled to a user can collect information regarding the user. A controller can use the collected information to determine an amount of medication to provide the user. The controller can instruct a drug delivery device to dispense the medication to the user. The drug delivery device can be a wearable insulin pump that is directly coupled to the user. The controller can be part of or implemented in a cellphone. A user can be required to provide a confirmation input to allow a determined amount of insulin to be provided to the user based on detected glucose levels of the user. The sensor, controller, and drug delivery device can communicate wirelessly.
Infants under 6 months of age at increased risk of both influenza (flu) and pertussis disease, and pregnant women risk serious illness and premature labor from flu. The Advisory Committee on Immunization Practices recommends that women receive a flu vaccine in flu season, and tetanus toxoid, reduced diphtheria toxoid, acellular pertussis (Tdap) vaccine during each pregnancy (ideally between 27-36 weeks) to lower the risk for flu and pertussis disease for themselves and their infants. However, only half of pregnant women in the US receive a flu and Tdap vaccine, respectively; only 33% of women receive both vaccines. Lack of vaccination stems from a combination of patient (lack of knowledge, vaccine hesitancy), provider (suboptimal communication skills, missed opportunities), and system (e.g. lack of standing orders and patient reminders) factors. An effective intervention is needed to improve flu and Tdap vaccination rates for pregnant women. To address these low vaccination rates the investigators plan to use a clustered RCT (randomizing practices), allocating half of the participating practice sites within each health system to the VAX-MOM intervention and the other half to standard of care. The multi-component VAX-MOM intervention will be comprised of: training in communication, provider prompts, standing orders, and feedback on vaccination rates.
The compsn. contains p-phenylenediamine (I) and o-aminophenol (II) or their cosmetically acceptable salts in a molar ratio such that after the addn. of an equal volume of 20 volume H2O2 and application to the hair for 30 mins. no Bandrowsky Base is detected in the compsn. The colourants are contained in a cosmetically acceptable medium. In one embodiment, the compsn. contains 1-2.5% (I) and the molar ratio is 2 or less. In another embodiment, less than 1% (I) is present and the molar ratio 3or less. In use, the compsn. is mixed with H2O2 or urea peroxide and applied for 10-30 mins. Alternatively, a compsn. contg. (II) is applied first, opt. followed by moderate rinsing, and then a compsn. contg. (I) and the oxidant is applied, the opt. rinsing being such that sufficient (II) remains. The combination avoids self coupling prod. of (I) or Bandrowsky base at the same time enabling the depth of shade previously conferred by this base, which can irritate the skin, by the novel coupling prod. of (I) and (II) which is 2-amino 5-(p-aminoaniliono)-N(p-aminophenyl-44-benzoquinonlimine.
This comprehensive systematic review and meta-analysis sought to investigate the impact of chia seed supplementation on obesity indicators and metabolic factors. Through a thorough search of relevant studies up to April 2024, 14 clinical trials involving 835 participants were included in the analysis. The findings revealed a notable decrease in triglyceride levels across both higher and lower doses of chia seeds, with weighted mean differences (WMD) of -8.69 mg/dL and -13.11 mg/dL, respectively. Additionally, a statistically significant reduction in LDL-C levels was observed solely in the higher dosage group, showing a WMD of -4.77 mg/dL. Moreover, although the decrease in systolic blood pressure (-2.78 mmHg) compared to the control group was statistically significant, it was only observed with the higher dosage. These results suggest that chia supplementation may offer beneficial effects on dyslipidemia, hypertension, and body weight, potentially mitigating the risk of cardiovascular disease.
The invention belongs to the technical field of medicines, and particularly relates to a melatonin flexible liposome, and a preparation method and application thereof. The melatonin flexible liposome is prepared from the following raw materials in parts by weight: 10-30 parts of lecithin, 70.00-90.00 parts of cholesterol and 10-30 parts of sodium deoxycholate. The melatonin flexible liposome has better percutaneous permeation effect. The results of pharmacokinetic experiments in rats show that the AUC of the flexible liposome is improved by 1.82 times compared with that of the common liposome, which indicates that the flexible liposome can improve the bioavailability of melatonin absorbed through skin. The results of pharmacodynamic experiments of mice show that the external flexible liposome has the function of resisting photoaging. The flexible liposome enters the body through the skin, changes the structures of stratum corneum lipid and keratin, and can resist skin damage caused by ultraviolet sunburn.
During the screening visit the patient will arrive at the study site and written informed consent will be obtained by the investigator. Inclusion and exclusion criteria will be controlled and blood will be drawn for HbA1c, the efficacy and the safety parameters. A POCT pregnancy test will be conducted in women of childbearing age. Patient demographics and history will be collect and a physical examination will be performed. The patient will complete a QoL questionnaire and will receive training about the de-escalation therapy approach. After all necessary biomarker results of the screening visit are accessible for the selection of the De-escalation treatment the treatment initiation visit will be performed. During this visit the investigator will use these results to determine a most optimal personalized treatment combination for regeneration of the pancreatic ß-cells within the next three months. An ECG will be recorded and the patient will be informed about his/her personalized treatment and its execution. The patient will receive the drugs in the volume required until the next visit. During the next two visits the patient will arrive at the investigational site at the agreed time-point and information regarding potential adverse events will be collected. Vital signs will be measured, and blood will be drawn for assessment of the efficacy parameters. Information about hypoglycaemia will be collected, and the patient will receive drug supply that lasts until the next visit. The patient will be instructed to stop the anti-diabetic medication 3 days before the next visit.

For the final visit (visit 5) the patient will arrive at the investigational site after an overnight fast and information regarding potential adverse events and hypoglycaemic events will be collected. Vital signs will be measured, and blood will be drawn for assessment of the efficacy parameters. An oral glucose challenge with 75 g of glucose will be conducted with blood draws for assessment of glucose and other biomarkers at time-points 0, 1h and 2h. The investigator will give a recommendation for the consecutive follow-up treatment requirements based on the results of the glucose challenge test. The patient will complete a QoL questionnaire (DTSQ) and this concludes study participation for the patient.
Extracellular deposits of amyloid-β (Aβ) in the form of plaques are one of the main pathological hallmarks of Alzheimer's disease (AD). Over the years, many different Aβ plaque morphologies such as neuritic plaques, dense cored plaques, cotton wool plaques, coarse-grain plaques, and diffuse plaques have been described in AD postmortem brain tissues, but correlation of a given plaque type with AD progression or AD symptoms is not clear. Furthermore, the exact trigger causing the development of one Aβ plaque morphological subtype over the other is still unknown. Here, we review the current knowledge about neuritic plaques, a subset of Aβ plaques surrounded by swollen or dystrophic neurites, which represent the most detrimental and consequential Aβ plaque morphology. Neuritic plaques have been associated with local immune activation, neuronal network dysfunction, and cognitive decline. Given that neuritic plaques are at the interface of Aβ deposition, tau aggregation, and local immune activation, we argue that understanding the exact mechanism of neuritic plaque formation is crucial to develop targeted therapies for AD.
The invention discloses lactobacillus plantarum. The lactobacillus plantarum is preserved in the China center for type culture collection (CCTCC) on September 22, 2016 and has a preservation number of CCTCC NO. M 2016512. The invention also discloses a method for fermenting fruit and vegetable juices by the lactobacillus plantarum. The lactobacillus plantarum is derived from marine brown algae kelp, can be used as a probiotic beneficial to human health and has a good flavor. The lactobacillus plantarum can resist salts, acids and bile salts, has a high internal survival rate after ingestion, can be used for fermentation of fruits and vegetables and has probiotic effects. The fermentation broth of the lactobacillus plantarum has alpha-glucosidase inhibitory activity and has the hypoglycemic effects.
Pharmaceutical compositions for the treatment of peripheral circulatory disturbances especially venous diseases e.g. thrombosis and varicose prophylaxis, non-cardiac oedemas and ulcus cruris varicosum having vasodilator activity and an increased tone of the veins effect comprise raubasine and/or a salt thereof e.g. phosphate (also known as ajmalicine, d  - yohimbine and pytetrahydrosepentine) in admixture with a sterile, injectable inert liquid pharmaceutical carrier in admixture with a solid inert pharmaceutical carrier, said compositions being in the form of dosage units each containing at least 10 mg raubasine and/or salt thereof.  The liquid carrier is preferably water optionally containing at least one solubiliser e.g. ethanol and/or stabiliser e.g. ethylene-diamine and/or buffer e.g. citrate or tartrate, and/or a viscosity regulator e.g. a liquid polyethylene oxide. Tablets for oral administration contain conventional solid excipients including flavouring and/or sweetening agents.
A cohort of elderly individuals between 65 and 80 years of age were vaccinated with Fluad, a seasonal inactivated trivalent adjuvanted influenza vaccine. Blood samples before (day 0) and at days 1/3, 7,21 and 70 after vaccination were collected.
The invention belongs to the pharmaceutical field, and concretely relates to a bromhexine hydrochloride compound, and a preparation method, a medicinal composition and a preparation thereof. An X-ray powder diffraction pattern obtained by measuring the bromhexine hydrochloride compound through using Cu-Kalpha ray is shown in figure 1. The invention also relates to the medicinal composition of the bromhexine hydrochloride compound, and a medical auxiliary material is selected from at least one of an excipient, a pH adjusting agent, a cosolvent and an osmotic pressure adjusting agent. The dosage form of the medicinal composition is lyophilized powder for injection, aseptic powder for injection, a high capacity injection or a low capacity injection. The bromhexine hydrochloride compound prepared in the invention has a good stability, has a higher water solubility than that in the prior art, and is very suitable for preparing various injections. Stability tests prove that the lyophilized powder for injection, the aseptic powder for injection, the high capacity injection and the low capacity injection prepared through using the bromhexine hydrochloride compound have a very good stability and are very suitable for clinical application.
Gemcitabine was administered over 30 minutes immediately following percutaneous irreversible electroporation. Gemcitabine was then given once weekly for 2 weeks, followed by a week of rest from treatment. Subsequent cycles consisted of once weekly infusions for 3 consecutive weeks out of every 4 weeks.Treatment continued until disease progression was detected by mRECIST or there was unacceptable toxicity.
Participants will be asked to consume a standardised breakfast at home before 09:00 for seven consecutive days. The energy content of the breakfast will be 25% of individual measured resting metabolic rate. Prior to the experimental conditions, the participants will select one wholegrain, high-fibre ready-to-eat cereals (with the option of adding raisins) and fruit juice from a limited selection. Thus, breakfast composition will be controlled within participants, but not between participants to account for individual preferences. To ensure that the correct amount of each breakfast item is consumed, food items will be provided to the participants in pre-packaged containers and the participants will be provided with a marked beaker to measure their milk and juice each morning. The only exception is that parents will be asked to provide the 1.8% milk.
Over the past decade, there has been an ongoing shift away from the use of opioids in the postoperative setting due to both their negative side effects and their high potential for dependence and abuse. Various new techniques for multimodal pain management are increasingly being utilized in adult orthopaedics, including injection of local anesthetics and analgesic agents. These techniques aim to block pain directly at the site of injection in order to reduce postoperative pain while minimizing systemic effects and preserving motor function, allowing for early mobilization. Numerous randomized controlled trials in both the arthroplasty and adult trauma populations have demonstrated reduced pain and narcotic consumption with local analgesia injection, but there is scant evidence on the efficacy of similar injections in pediatric surgical patients. While robust evidence demonstrating both safety and efficacy of these injections has led to routine use in the adult orthopaedic population, use in pediatric patients still remains limited, likely due to a lack of level I therapeutic evidence.

Local anesthetic injections offer several theoretical advantages over current pain management modalities. When compared with other methods of anesthesia, including epidural anesthesia or some peripheral nerve blocks, local anesthetic injections preserve motor function, allowing for early mobilization and rehabilitation. Additionally, they do not require specialized equipment or anesthesia personnel and can be administered in the operating room without significantly affecting the duration of the procedure. While a mainstay in traditional pain management protocols, epidural anesthesia in the pediatric CP population poses specific risks including damage to preexisting intrathecal baclofen pumps and iatrogenic infection. Moreover, epidural insertion can be a technically demanding procedure in these patients given high rates of concomitant neuromuscular scoliosis. Prior retrospective studies comparing peripheral nerve and lumbar plexus blocks compared to epidural anesthesia have shown mixed results in decreasing pain scores and opioid use in this patient population. As described in Preliminary Data section below, the investigators' pilot randomized control trial demonstrated significantly decreased pain scores and narcotic use postoperatively in pediatric patients with CP who received multimodal analgesia injection compared to placebo while undergoing hip surgery. The present study aims to substantively contribute to current literature by providing level I evidence comparing the safety and efficacy of surgical site injections with epidural anesthesia in a patient population for whom pain management remains challenging.
In the control group, a blood pressure cuff, same as the cuff in the RIC group, will be placed on both upper arms of the patients but only pressurized to 60 mmHg. The rest of the procedures will be the same.
Background: Ageing is associated with an increased risk of cognitive decline. Vitamin D plays an important role in many of the symptoms and conditions related to advanced age, including impaired balance, falls and osteoporosis. Vitamin D also has a physiological effect on the function of the central nervous system, and studies have suggested a relationship between this vitamin and changes in cognitive function of older people. The investigators propose a pilot study to evaluate the effect of vitamin D supplementation on the neurocognitive function of older people.

Methods: A total of 30 subjects of both genders older than 65 years with levels of 25-OH Vitamin D lower than 30 ng/ml on routine laboratory screening will be included in the study. Exclusion criteria will include any unstable medical condition as determined by the treating physician, a diagnosis of dementia, the use of supplements containing vitamin D in any dose, significant visual or hearing impairment not corrected by spectacles or hearing aids, and a level of literacy that limits the performance of computerized neurocognitive testing. Following provision of written informed consent for inclusion in the study, subjects will answer a questionnaire providing demographic details, undergo cognitive screening by use of the MoCA test, and computerized cognitive assessment using the Neurotrax battery. All subjects will undergo repeat testing for level of 25-OH Vitamin D, and where below-normal levels are confirmed patients will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months. Levels of serum calcium will be repeated monthly (end of month 1, 2, 3). At 3 months subjects will undergo repeat testing for level of 25-OH Vitamin D, and repeat computerized cognitive assessment using the Neurotrax battery.
Particles  for  delivery of an  active  agent  to  the alveoli of a hum comprise the active agent and at least  40% by  weight  of hygroscopic growth inhibitor.  The  inhibitor is   selected  from  beta-cyclodextrin,  hydroxypropyl-beta- cylcodextrin,       sulfobutylether       beta-cyclodextrin, hydroxyethylstarch,  dextranomer  and  maltodextrins.    The inhibitor  is  incorporated within  the  particles  and  the particles  exhibit a drop in emitted dose  under  stimulated lung  condition  of no more than about 25%.  Preferably  the active  agent  is  a  protein or polypeptide  selected  from calcitonin  or insulin.  The particle as can be prepared  by a  method  comprising preparing a mixture of at least  about 40% by weight (solids) of a hygroscopic growth inhibitor  as described  above,  an  active  agent  and  a  solvent.   The mixture  is then spray dried to obtain homogenous  particles of  the  hygroscopic growth inhibitor and the active  agent. Also  described is method for increasing the quantity of  an inhaled  active agent deposited in the deep lung  comprising incorporating  into  active  agent-containing   dry   powder particles for inhalation at least about 40% by weight  of  a hygroscopic  growth  inhibitor so that  upon  aerosolization and  inhalation of the particles at lest 20% of the  nominal dose is deposited in the deep lung.
Atrial fibrillation (AF) is a common clinical malignant arrhythmia with an increasing global incidence. Ion channel dysfunction is an important mechanism in the development of AF. In this study, we used bibliometrics to analyze the studies of ion channels and AF, aiming to provide inspiration and reference for researchers. A total of 3179 literature citations were obtained from Web of Science core databases. Analysis software included Excel 2019, VOSviewer 1.6.16, and CiteSpace 5.7.R2. This field of research has been growing since 1985. The most active country is the United States. The University of Montreal is the most important research institution. The journal Cardiovascular Research has published the largest number of articles in this field. Stanley Nattel and Dobromir Dobrev are the most frequently cited authors. The most cited literature was published in Nature and Science. Cardiac electrophysiology, gene expression, pathogenesis of AF, and AF prevention and treatment are the hot topics for this field research. Cardiac fibrillation and catheter ablation may be future research hotspots in this field.
During the last decade a considerable clinical experience has been accumulated with the use of drug eluting coronary stents with durable polymers, that permanently cover the metallic stent scaffold, allowing the local delivery of anti-restenotic agents. However durable polymers have been associated with an increased risk of late and very late stent thrombosis and the anticipated development of in stent neo-atherosclerosis. Since permanent polymer coatings may have pro-inflammatory effects, with delayed healing and prolonged endothelial dysfunction, current research on DES has focused on the use of biodegradable polymer coatings, which disappear after a short period of drug-release (3-4 months). Current clinical guidelines recommend at least 6-12 months of dual antiplatelet therapy (DAPT) after DES implantation,in order to prevent ST. Recent data obtained by pooled analyses of ZES, support a significant reduction of the DAPT to the same range used with bare metal stents. The substantial delays in DES healing observed from multiple human pathology series and in-vivo studies using Optical Coherence Tomography (OCT) were not assessed as risk factors for prolonged used of DAPT. However different patient cohorts might have different responses to stent implantation. In addition, there is no comparative evidence on long term development of neo-atherosclerosis in bioabsorbable versus permanent polymer DES. OCT allows precise assessment of stent strut apposition and coverage and accurate measures of different tissue components of neoatherosclerosis. This study is the first attempting to characterize the early and late vascular responses to novel bioabsorbable polymer EES (SYNERGY™) compared with a permanent polymer benchmark novel generation ZES (RESOLUTE INTEGRITY™) .The stent comparator has been selected due to the large use across the interventional cardiology community and the recent approval from European Regulators Authorities to update the CE (Conformité Européenne) mark labeling to only one-month duration of dual anti-platelet therapy.